A Pilot Study of Gemcitabine Plus High-Dose Ascorbate in Locally Advanced Unresectable or Metastatic Soft Tissue and Bone Sarcomas Including Adolescents
Latest Information Update: 24 Feb 2023
At a glance
- Drugs Ascorbic acid (Primary) ; Gemcitabine (Primary)
- Indications Bone cancer; Haemangiosarcoma; Liposarcoma; Myxoid liposarcoma; Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- 20 Feb 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 16 Sep 2022 Planned End Date changed from 31 May 2023 to 31 May 2025.
- 16 Sep 2022 Planned primary completion date changed from 31 May 2023 to 31 May 2025.